Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Odette S ReifsniderAnuraag R KansalJennifer FrankeJoseph LeeJyothis T GeorgeMartina BrueckmannStefan KaspersSarah B BrandAnastasia UstyugovaStephan LindenMatthew StargardterNikco HauPublished in: ESC heart failure (2020)
This analysis suggests that adding empagliflozin to SoC in HF patients with T2D constitutes a cost-effective use of UK healthcare resources and may provide long-term health benefits to patients.
Keyphrases
- healthcare
- heart failure
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- public health
- ejection fraction
- cross sectional
- peritoneal dialysis
- prognostic factors
- clinical trial
- left ventricular
- acute heart failure
- atrial fibrillation
- human health
- cardiac resynchronization therapy
- patient reported
- open label